Register
Login:
Share:
Email Facebook Twitter




Add Vernalis to quick picks

Vernalis Share Price (VER)



Share Price Information for Vernalis (VER)


Share Price: 78.25Bid: 78.25Ask: 78.50Change: 0.00 (0.00%)No Movement on Vernalis
Spread: 0.25Spread as %: 0.32%Open: 78.25High: 78.25Low: 78.25Yesterday’s Close: 78.25

Vernalis Plc Ord 1P

Vernalis is listed in the FTSE AIM 100, FTSE AIM All-Share
Vernalis is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
78.25

Share Price SpacerBid
78.25

Share Price SpacerAsk
78.50

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
192,021

Share Price SpacerOpen
78.25

Share Price SpacerHigh
78.25

Share Price SpacerLow
78.25

Share Price SpacerClose
78.25

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 443.44m £346.99m 10,000

52 Week High 85.00 52 Week High Date 13-AUG-2015
52 Week Low 42.25 52 Week Low Date 12-SEP-2014

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
14 174,371 17,650 -86.944 -0.90 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

28-Aug-15
16:35:25
78.25
755
Sell* 
78.25
78.50
590.79
UT 
Trade Type:
Uncrossing Trade

28-Aug-15
16:21:12
78.0318
6,396
Buy* 
74.75
78.25
4,991
Trade Type:
Ordinary

28-Aug-15
16:08:36
78.25
5,379
Buy* 
74.75
78.25
4,209
Trade Type:
Automatic execution


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Vernalis trades >>

Directors Deals for Vernalis (VER)
Trade DateActionNotifierPriceCurrencyAmountHolding
05-May-15Buy
Trade Notifier Information for Vernalis
Nigel Sheail held the position of Non-Executive Director at Vernalis at the time of this trade.
 Nigel Sheail
59.9GBX84,000294000
13-Oct-14Buy
Trade Notifier Information for Vernalis
Nigel Sheail held the position of Non-Executive Director at Vernalis at the time of this trade.
 Nigel Sheail
48.7GBX103,000210000
26-Apr-13Buy
Trade Notifier Information for Vernalis
Nigel Sheail held the position of Non-Executive Director at Vernalis at the time of this trade.
 Nigel Sheail
23GBX107,000107000
View more Vernalis directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
22 Aug '15
Edenfund
Brokers
74.25
No Opinion

3 brokers N1 SINGER, CANACCORD,STIFEL NICHOLAS have all reiterated their buy recommendations at 96P 73P 103P respectively.
21 Aug '15
a4007035
Re Spup
78.00
No Opinion

Yeah it's a definite overreaction. Trading results released will hopefully rest some fears. Plenty of upside potential. And we've barely touched the tip of the iceberg. Sp should stabilise around 70. So not much point in selling. I've been long on this one for a while
21 Aug '15
Edenfund
RE: Spup
73.50
No Opinion

I think a bit of profit taking as the rest of the market is in a tailspin.lots more to come from vernalis a good buying opportunity i would have thought.always have to be aware of disappointing news investing in biotech's and adverse share price reactions.
21 Aug '15
a4007035
Spup
73.50
No Opinion

Are you seriously thinking about bailing? VER is about to make profit for the first time. You should be investing more if anything. We are still yet to see the fruits of the cough cold medicine. The latest news is a very minor setback and in the grand scheme of things means actually very little. You're always going to get R&D projects that are scrapped. It's just the nature of the sector.
20 Aug '15
GedW
Proof of Content study update
80.75
No Opinion

Announces the results from a Phase II proof-of-concept (POC) study of V158866, its fatty acid amide hydrolase (FAAH) inhibitor, which is being investigated as a treatment for neuropathic pain as a result of spinal cord injury. In the randomised, double-blind, placebo-controlled, two-period cross-over study, although dosing of V158866 resulted in elevated endocannabinoid levels, on an intent-to-treat basis the study failed to meet its pain reduction primary endpoint. Treatment with V158866 did however show a trend towards efficacy on a per protocol basis (p=0.054) and was generally well tolerated. Consistent with its strategy of becoming a commercial business, Vernalis is not planning to make any further investment in this programme and will seek to realise its potential value through partnering. A previous Phase I study provided encouraging data in evaluating the safety, tolerability and pharmacokinetic and pharmacodynamic effects of the compound. Ian Garland, CEO of Vernalis commented "The goal of this study was to identify a therapeutic setting for this programme. Its completion ends the investment in our NCE pipeline and we aim to partner the remaining unpartnered programmes to realise value where possible. The key focus of the organisation remains the transition of Vernalis to a commercial company, with the forthcoming launch of Tuzistra™ XR, our extended release cough cold product for the US prescription market, which is progressing as planned ".
18 Aug '15
toatie
spup
81.25
No Opinion

very nice appointment ,Vernalis plc - Appointment of Non-Executive Director Vernalis plc announces that Ms Lisa Amster Schoenberg, aged 48, has been appointed to the Board as a Non-Executive Director with effect from 1 September 2015. Ms Schoenberg has extensive marketing experience of pharmaceutical products in both primary and secondary care in the US. For the past two years, she has acted as pharmaceutical marketing consultant to a number of organisations. From 1993 until 2013 Ms Schoenberg worked for AstraZeneca Pharmaceuticals (US) in a number of senior marketing positions, culminating as VP Sales & Marketing, Growth Brands USA. After graduating from the University of Michigan in 1988, Ms Schoenberg joined Amster & Co as Financial Analyst. She then undertook an MBA at Wharton School, University of Pennsylvania, specialising in Healthcare Management and Marketing, before joining AstraMerck in 1993. Peter Fellner, Chairman of Vernalis plc, commented: "I am delighted to welcome Lisa to the Vernalis Board. Her experience in launching and commercialising products in the US market in both primary care and speciality medicines and her knowledge of the changing US marketing environment and how it is likely to evolve will be invaluable for the Board. We look forward to her contribution, as we continue to build value for Vernalis' shareholders." spup

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Vernalis (VER) >>
Please Login or Register to post messages



Vernalis Plc Ord 1P home pageWebsite: Vernalis Plc Ord 1P
Website Description: Vernalis corporate website



Sign up for Live Prices




Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.